Introduction
Autoimmune Lymphoproliferative Syndrome (ALPS) is a recently described disorder of disrupted lymphocyte homeostasis. Patients with ALPS have mutations in the Fas apoptotic pathway, leading to abnormal lymphocyte survival resulting in chronic lymphoproliferation and a breakdown in immunologic tolerance. ALPS was first characterized in 1992 in a group of patients who were found to have chronic lymphoproliferation, autoimmune manifestations, and an increased number of double negative T cells (DNTs; cell phenotype CD4-/CD8-, CD3+, TCRαβ+). 1 These patients shared similar clinical features with two mouse models of autoimmunity, lpr and gld.
These mice were later found to have defective Fas-mediated apoptosis with homozygous mutations in the Fas gene and Fas ligand gene, respectively.
2,3
Such patients with autoimmunity and lymphoproliferation were proposed 4 and later confirmed 5 to have similar genetic defects to the lpr and gld mice and were classified as having ALPS.
ALPS is a thought to be a rare condition and since the original report of ALPS only a few hundred cases have been reported. 6 Apoptotic pathways are important for maintaining lymphocyte homeostasis by eliminating excess activated, antigen-driven, and auto-reactive cells. Fas, a member of the tumor necrosis (TNF) receptor family, is normally highly expressed in activated B and T cells. 7 Fas is activated by binding to the protein Fas ligand which is highly expressed in activated T lymphocytes. The interaction of Fas and Fas ligand leads to multiple intracellular reactions, culminating in the activation of the caspase cascade and cellular apoptosis. The Fas apoptotic pathway is crucial for the downregulation of the immune response and in its absence patients develop chronic lymphoid hyperplasia and
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From autoimmunity. 8 The majority of patients with ALPS have mutations in the Fas 9 gene, but mutations in Fas ligand 10 , caspase 8 11 , and caspase 10 12 have been found. No mutation is defined in up to 24% of patients. 8, 13, 14 Clinical manifestations in patients with ALPS vary but typically include autoimmune cytopenias, lymphoproliferation with lymphadenopathy and organomegaly, and a propensity to develop secondary neoplasms. In the largest published series of ALPS patients, 15 all patients had lymphoproliferation and the majority but not all patients had autoimmune cytopenias. Risk of secondary malignancy is thought to approach 10%. 15 Other infrequent manifestations include autoimmune liver and kidney disease and vasculitis. 15 The current diagnostic criteria as proposed by the National Institutes of Health (NIH) ALPS group 15 are listed in Table 1 . 17 The underlying pathophysiology of ES is unknown but is thought to be secondary to generalized immune dysregulation.
ES is a diagnosis of exclusion and other confounding disorders must be ruled out before establishing the diagnosis. 18 Infections, rheumatological diseases, and malignancies can present with autoimmune cytopenias and patients with these conditions do not, by definition, have ES.
19
ES patients frequently have other symptoms in addition to their autoimmune manifestations, which may include lymphadenopathy, hepatomegaly, and splenomegaly. In one published series over half of patients with ES had evidence of lymphoid hyperactivity. 20 Based on this clinical overlap between ALPS and ES, we hypothesized that a subset of patients diagnosed with ES may have ALPS. This is the first report examining patients with ES for ALPS.
Methods

Patients
A review of clinical records identified 20 patients who were followed at The
Children's Hospital of Philadelphia over the period 1999-2004 with a diagnosis of ES.
Patients were eligible if they 1) carried the diagnosis of ES and 2) were being actively followed (defined as at least one visit in past year). Patients were excluded from this study if autoimmune cytopenias were associated with systemic lupus erythematosis, malignancy, or treatment with immunosuppresion following solid organ transplant.
Similarly, patients with genetic abnormalities known to predispose to autoimmune cytopenias were excluded. Of the 20 identified ES patients, one with DiGeorge The clinical immunology lab designed the testing protocol based on published techniques 21 and evaluated 22 healthy adult controls to establish normal parameters.
Normal was defined as 2 standard deviations from the mean and 2.6% CD4-/CD8-, CD3+, TCRαβ+ cells was determined to be the threshold for the normal range using the gating strategy detailed below. In addition, the clinical laboratory periodically recalculated the mean and standard deviation based on series of tested controls. Thus far, over fifty control samples have been tested with no change in mean or standard deviation.
Whole blood from each patient sample and normal control was stained in two tubes with monoclonal antibodies purchased from Beckman Coulter. The first tube was an isotype control tube and contained anti-CD3-FITC, mouse IgG1-RD1, and mouse IgG2a-PC5. The second tube contained anti-CD3-FITC, anti-CD4-RD1, anti-CD8-RD1, and anti-TCRαβ-PC5. After staining, the erythrocytes in each tube were lysed using the 
Testing for Fas-mediated Apoptosis
Fas-mediated apoptosis was evaluated using published techniques. 4, 22, 23 All patient samples were tested in tandem with a normal control. We used a panel of ten different adult volunteers as normal controls (12 total patients; 10 total controls). Each normal control was used in 1-3 experiments. PBMCs were isolated by Ficoll gradient centrifugation and resuspended at concentration of 10 6 cells/ml in RPMI 1640 with 10%
fetal calf serum plus rhIL-2 (25 U/ml, Leinco). To allow confirmatory testing, T cells were stimulated with two different mitogens. In one well, T cells were stimulated with phytohemagglutinin (PHA) (3ug/ml) and re-stimulated with PHA (1ug/ml) on day 8-14.
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From Apoptosis assays were performed 6 days after second stimulation. In the second well, T cells were stimulated with phorbol 12-myristate 13-acetate (PMA) (10ng/ml) and A23187 (Calcimycin) (500ng/ml) and apoptosis assays were performed in 3-5 days. The published protocols assessing Fas-mediated apoptosis in the ALPS literature are based on PHA stimulation of T cells. 4, 22, 23 Recent work has shown PMA and A23187 is as effective in stimulating T cells for subsequently evaluating the Fas apoptotic pathway.
PMA is a more potent mitogen, requiring a shorter culture period before performing assays. 24 We compared the two mitogens in each sample. After stimulation, T cells were aliquoted into 24 well plates at a concentration of 50,000 cells per well. Cells were incubated with control media, anti-Fas monoclonal antibody (IgM, 10ug/ml for PMA assay and 1ug/ml for PHA assay, Upstate), steroid [either dexamethasone (10uM, Sigma)
or methylprednisolone (1uM, Pharmacia)] or C2-ceramide (50uMol, Sigma) for 24-48 hr.
Induction of cell death was evaluated by trypan blue exclusion and verified with FACS analysis for Forward Scatter/Side Scatter (FSC/SSC) and 7-AAD (BD Pharmigen).
Trypan blue exclusion was performed by adding 11ul trypan blue dye (Cellgro) to 100 ul cell suspension and counting number of viable cells using light microscopy at 20x power.
For FACS analysis, human lymphocytes both stimulated with mitogen and freshly obtained were used as isotype controls. Dead cells were defined as those displaying shrunken/hypergranular morphology on FSC/SSC and those which stained with 7-AAD.
We used control stimulated T cells treated with 100% Ethanol to set parameters for dead cells on 7AAD staining. To qualify as a positive test (consistent with death with stimuli)
there must be at least both a three fold and 40% increase in cell death by both FACS and trypan blue. 
had chronic disease with frequent exacerbations (>2 times a year requiring immunosuppressive medications). One third of the patients (4/12) had a history of lymphadenopathy (defined as non-infectious, non-malignant enlargement of at least two nodal groups). Two of these patients had persistently enlarged lymph nodes >2cm in multiple (>3) nodal regions. The other two patients had enlarged lymph nodes >2cm in multiple nodal regions; however, the enlarged nodes and the areas involved waxed and waned. One half (6/12) of the patients had a history of chronic organomegaly (enlarged greater 6 months). All four patients with a history of lymphadenopathy also had a history of chronic organomegaly. Two patients, therefore, had isolated organomegaly. Two additional patients were noted to have splenomegaly during episodes of AIHA but did not have chronic organomegaly. One third (4/12) of the patients with splenomegaly had undergone splenectomy as part of the management of their cytopenias. Prior to splenectomy, all four of these patients had spleens which were chronically enlarged at least 3-4cm. Of the other two patients with splenomegaly who did not undergo splenectomy, both had a persistently enlarged spleen at least 2cm below the costal margin. Four patients had a history of intermittent hepatomegaly. All of these patients also had a history of chronic splenomegaly. One half (6/12) of the patients had a history of clinical chronic nonmalignant lymphoproliferation (lymphadenopathy and/or organomegaly), potentially consistent with ALPS. 25% (3/12) of the patients had comorbid conditions, including atopy, nephrotic syndrome, and diabetes mellitus. No patient had a history of malignancy or life threatening infection. 58% (7/12) of the ES patients had elevated DNTs. Examples of a positive and negative DNT test are depicted in Figure 1 . All patients were then tested for Fas- Patients with defective Fasmediated apoptosis (consistent with ALPS) are depicted with black columns and patients with normal apoptosis (not consistent with ALPS) are depicted with white columns. The ordinate depicts percent DNTs and the bold line the cutoff for an elevated result (2.6%). All patients except one (number 5) with elevated DNTs had defective Fas-mediated apoptosis. All patients with normal DNTs had normal apoptosis 5/6 of the ES patients with defective Fas-mediated apoptosis and elevated DNTs also had a history of lymphadenopathy or organomegaly, while one did not. Of the seven patients with elevated DNTs, six had functional confirmation of defective Fas-mediated apoptosis. Thus, there was one false positive and the specificity of the DNTs test was 85.7% in this series. Of the six patients with normal DNTs, none had functional confirmation of defective Fas-mediated apoptosis. Thus, there were no false negatives and the sensitivity of the test was 100% for this series. Summary results comparing results of DNTs to apoptosis assay are depicted in Figure 4 and Table 2 .
Pathology specimens were available for analysis on two patients who met diagnostic criteria for ALPS and one who did not. One of the biopsies from one of the patients with laboratory evidence of ALPS was strongly suggestive of a diagnosis of ALPS with classic features, elevated DNTs by immunohistochemical stains, paracortical expansion, and follicular hyperplasia. Another biopsy from one of the patients with laboratory evidence of ALPS was suggestive of ALPS but was not as conclusive. This biopsy was a poor specimen and was obtained from a normal sized lymph node. The node showed elevated DNTs by immunohistochemical stains and follicular hyperplasia; however, because of the quality of the specimen it was also potentially consistent with a reactive node. The biopsy from the patient who did not meet laboratory diagnostic criteria for ALPS was also not consistent with ALPS, revealing a reactive lymph node with normal DNTs by immunohistochemical stains.
Discussion
We studied a group of 12 patients with Evans syndrome for the laboratory characteristics of ALPS: elevated DNTs and defective Fas-mediated apoptosis of mitogen-stimulated T cells. Based on this testing, we found an unexpectedly high prevalence of abnormal laboratory findings highly suggestive of ALPS among patients diagnosed with ES. Our data further suggest that DNTs may serve as a sensitive marker of patients who need further definitive testing. Identifying patients who have been Of interest, our clinical laboratory established a different normal range for DNTs then is cited in the literature. In our laboratory, after healthy controls were tested, 2.6% was determined to be the threshold for normal range, likely as a result of our highly gated analytic strategy. The normal cutoff for DNTs varies from institution to institution and
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From different series publish different normal ranges. 6, 13 The current accepted definition of ALPS includes a result of >1% DNTs as one of the diagnostic criterion. Thus, it is important to know the normal values of an institutional laboratory. As is described in the literature, 29 healthy adults were used to establish normal parameters for DNTs since DNTs have not been found to change with age. 6 Four patients in our study were taking immunomodulating medications at time of evaluation for DNTs. Three of these patients were taking low dose (5mg or less) every other day steroids. Two of these patients had elevated DNTs and defective Fas mediated apoptosis and one of these patients had normal DNTs and normal Fas mediated apoptosis.
Similar doses of steroids have not been shown to affect DNT or apoptosis analysis. ALPS is presumed to be a rare diagnosis with only a few hundred reported cases. 6 Our finding a high prevalence of ALPS in ES, a more common condition, argues that ALPS may be more common than previously thought. An assessment of the true prevalence of ALPS within patients diagnosed with ES awaits a larger prospective study.
Because of the selection bias inherent in retrospectively assessing patients at a tertiary referral center, the prevalence of ALPS assessed by a prospective study could be lower than we have observed here.
In addition to ALPS, another disorder with autoimmunity and lymphoproliferation has been described, Autoimmune Lymphoproliferative Disease (ALD 34 No patients in our series had a co-morbid disorder associated with defective Fas mediated apoptosis except one patient had diabetes mellitus. This patient had normal Fas mediated apoptosis and normal DNTs.
In summary, in the group of 12 ES patients tested in our study, 58% had elevated DNTs suggestive of ALPS, with functional confirmation in 6/7 tested. Our data suggest that DNTs may be a sensitive first line-screening test and may serve as a marker that identifies patients who require definitive testing. Our preliminary findings suggest a high prevalence of ALPS among ES patients, a novel finding with important implications.
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